Smith+Nephew Launches CARTIHEAL Implant Across Key European Markets
SNN expands CARTIHEAL's reach across 12 European markets, backed by five-year clinical data and strong momentum in its Sports Medicine Joint Repair business.
Smith+Nephew Launches EVOS PELVIC System to Advance Trauma Care
SNN expands its trauma portfolio with the EVOS PELVIC System, targeting complex pelvic and acetabular fracture procedures in the United States.
SNN Advances Surgical Robotics Through Imperial College Partnership
Smith+Nephew's five-year Imperial College London partnership targets less invasive robotic surgery and could speed research into clinical use.
Smith & Nephew SNATS Q2 Earnings Call Highlights
Smith & Nephew SNATS NYSE: SNN reported second-quarter underlying revenue growth of 1.6%, below management's expectations, as continued strength in Sports Medicine and ENT was offset by weakness in U.S. Orthopaedics and Advanced Wound Bioactives.
Smith & Nephew plc (SNN) Q2 2026 Earnings Call Transcript
Smith & Nephew plc (SNN) Q2 2026 Earnings Call Transcript
Smith+Nephew Launches LYNX COBLATION Wand for ENT Airway Surgery
SNN launches the LYNX COBLATION Laryngeal Wand, combining precise dissection, rapid debulking and hemostasis for airway procedures.
Smith & Nephew: Ongoing Business Progress And A More Attractive Price
Smith & Nephew continues to demonstrate solid business recovery, with robust revenue, profit, and free cash flow growth across all divisions. SNN's 2026 outlook targets 6% underlying revenue growth, 8% organic trading profit growth, and $800 million in free cash flow, with a new $500 million share buyback announced. Completion of the 12-point plan delivered mixed results: revenue growth targets were met, but trading margin fell short, prompting a new 'RISE' strategy with 2028 financial targets.
Smith & Nephew plc (SNN) Shareholder/Analyst Call Transcript
Smith & Nephew plc (SNN) Shareholder/Analyst Call Transcript
Smith & Nephew plc (SNN) Q1 2026 Sales/Trading Call Transcript
Smith & Nephew plc (SNN) Q1 2026 Sales/Trading Call Transcript
SNN vs. BSX: Which Stock Is the Better Value Option?
Investors interested in Medical - Products stocks are likely familiar with Smith & Nephew (SNN) and Boston Scientific (BSX). But which of these two stocks presents investors with the better value opportunity right now?
SNN's CARTIHEAL Cartilage Implant Beats Standard Care in 5-Year Study
Smith+Nephew's CARTIHEAL implant shows superior 5-year outcomes vs. standard care, with a new CPT code set to boost adoption and expand cartilage repair reach.
SNN Launches ALLEVYN COMPLETE CARE Dressing for Wound Management
Smith + Nephew launches ALLEVYN COMPLETE CARE foam dressing for wound management, expanding its Advanced Wound Management portfolio.
